SCHEMBL7320752

SCHEMBL7320752

COc1cc2c(cc1OC)C(c1ccccc1)CNCC2

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 15/20 0.81
DRD5 P21918 5/20 0.81
DRD2 P14416 8/20 0.64
KDM4E B2RXH2 3/20 0.64
HPGD P15428 3/20 0.64
MAPT P10636 2/20 0.64
CYP3A4 P08684 2/20 0.64
ADCY6 O43306 1/20 0.64
ADCY3 O60266 1/20 0.64
ADCY9 O60503 1/20 0.64
ADCY5 O95622 1/20 0.64
ADCY8 P40145 1/20 0.64
ADCY7 P51828 1/20 0.64
ADCY2 Q08462 1/20 0.64
ADCY1 Q08828 1/20 0.64
ADCY4 Q8NFM4 1/20 0.64
CYP2C9 P11712 1/20 0.64
NFKB1 P19838 1/20 0.64
THPO P40225 1/20 0.64
HIF1A Q16665 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7620194 1.00 DRD1 (0.81) DRD1DRD5DRD2KDM4EHPGD
SCHEMBL7621209 1.00 DRD1 (0.81) DRD1DRD5DRD2KDM4EHPGD
SCHEMBL11710309 0.92 DRD1 (0.73) DRD1DRD5DRD2KDM4EHPGD
SCHEMBL10745206 0.90 DRD1 (0.74) DRD1DRD5DRD2KDM4EHPGD
SCHEMBL11103715 0.90 DRD1 (0.70) DRD1DRD5DRD2KDM4EHPGD
SCHEMBL11103721 0.90 DRD1 (0.70) DRD1DRD5DRD2KDM4EHPGD
Hydrochloric Acid SCHEMBL10748542 0.90 DRD1 (0.70) DRD1DRD5DRD2KDM4EHPGD
SCHEMBL11103719 0.90 DRD1 (0.70) DRD1DRD5DRD2KDM4EHPGD
SCHEMBL10345411 0.90 DRD1 (0.70) DRD1DRD5DRD2KDM4EHPGD
Hydrochloric Acid SCHEMBL10745319 0.89 DRD1 (0.69) DRD1DRD5DRD2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4160765-A Method for 6-bromination of 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds SMITHKLINE CORPORATION (US) 1979-07-10 US claimed
JP-4005275-A None JP disclosed
EP-2332921-B1 8-Chloro-1 -methyl-2,3,4,5-tetrahydro-1 H-3benzazapine Hydrochloride ARENA PHARM INC (US) 2016-03-02 EP disclosed
EP-2189448-B1 Processes for the Separation of 3-Benzazepine Racemates ARENA PHARM INC (US) 2014-01-29 EP disclosed
US-20020019389-A1 Urea derivative useful as an anti-cancer agent and process for preparing same CHACONNE NSI CO., LTD. (KR) 2002-02-14 US disclosed
JP-H045275-A 1-PHENYL-N(2-CHLOROETHYLCARBAMOYL)-7,8-DIMETHOXY-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND PREPARATION THEREOF N I SEKTOR PRI VISSH MACHNO ELEKTROTECH INST LENIN 1992-01-09 JP disclosed
US-4359464-A 3-Furylmethyl-6-halo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines and antihypertensive use thereof SMITHKLINE BECKMAN CORPORATION (US) 1982-11-16 US disclosed
US-4352754-A HYPOTENSIVE, ANTI-PARKINSON SMITHKLINE CORPORATION (US) 1982-10-05 US disclosed
EP-0026505-B1 7,8-SUBSTITUTED-1-PHENYL-2,3,4,5-TETRAHYDRO-1-H-3-BENZAZEPINES SMITHKLINE BECKMAN CORPORATION (US) 1982-09-15 EP disclosed
EP-0002327-B1 PHARMACOLOGICALLY ACTIVE 6-LOWER ALKYL-7,8-DIHYDROXY-1-PHENYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES, METHOD OF PREPARING THEM AND INTERMEDIATES SMITHKLINE BECKMAN CORPORATION (US) 1982-08-04 EP disclosed
US-4255422-A DIURETICS, TREATMENT OF CARDIOVASCULAR DISORDERS SMITHKLINE CORPORATION (US) 1981-03-10 US disclosed
US-4206210-A PARKINSON'S DISEASE SMITHKLINE CORPORATION (US) 1980-06-03 US disclosed
US-4192872-A ANTI -PARKINSONISM ACTIVITY SMITHKLINE CORPORATION (US) 1980-03-11 US disclosed
US-4172890-A CARDIOVASCULAR, PARKINSON'S DISEASE, DOPAMINERGIC SMITHKLINE CORPORATION (US) 1979-10-30 US disclosed
US-4165372-A 6-Carboxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds and use as dopaminergic agents SMITHKLINE CORPORATION (US) 1979-08-21 US disclosed
US-4160765-A Method for 6-bromination of 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds SMITHKLINE CORPORATION (US) 1979-07-10 US disclosed
EP-0002327-A1 Pharmacologically active 6-lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, method of preparing them and intermediates SMITHKLINE BECKMAN CORPORATION (US) 1979-06-13 EP disclosed
US-4108989-A TREATING PARKINSON*S DISEASE, CARDIOVASCULAR DISORDERS SMITHKLINE CORPORATION (US) 1978-08-22 US disclosed
US-4052506-A BENZAZEPINES SMITHKLINE CORPORATION (US) 1977-10-04 US disclosed
US-4011319-A STIMULATING DOPAMINE RECEPTORS, RENAL VASODILATORS, DIURETICS SMITHKLINE CORPORATION (US) 1977-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019389-A1 Urea derivative useful as an anti-cancer agent and process for preparing same UTS2R, SLC14A1, URB2 DRD1 3415/4885DRD5 3091/4885DRD2 4158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.